News
October 02, 2025
Lyme Disease Market Growth Highlighted by Pipeline Advances and Expanding Patient Population | DelveInsight
According to DelveInsight’s analysis, the market for Lyme disease is anticipated to increase during the forecast period (2025–2034), owing to the launch of emerging therapies such as Valneva and Pfizer’s VLA15 and Tarsus Pharmaceuticals’ TP-05, Moderna’s mRNA-1982 and mRNA-1975, and others, and healthcare spending globally. According to DelveInsight’s analysis, the market for Lyme disease is anticipated to increase during the forecast period (2025–2034), owing to the launch of emerging therapies such as Valneva and Pfizer’s VLA15 and Tarsus Pharmaceuticals’ TP-05, Moderna’s mRNA-1982 and mRNA-1975, and others, and healthcare spending globally.
The Lyme disease treatment market is poised for significant growth over the next decade, fueled by promising new therapies and a rising number of patients, according to a new analysis by DelveInsight. The report projects a substantial market increase between 2025 and 2034, driven by the anticipated introduction of innovative treatments currently in the pipeline.
Lyme disease, a bacterial infection transmitted through the bite of infected blacklegged ticks, can cause a range of symptoms, from fever and fatigue to more serious complications affecting the joints, heart, and nervous system. The current treatment landscape primarily relies on antibiotics, but the emergence of new therapies offers hope for improved patient outcomes and preventative measures.
DelveInsight’s analysis highlights several key players and their groundbreaking approaches. Valneva and Pfizer are jointly developing VLA15, a vaccine designed to prevent Lyme disease by targeting the outer surface protein of the Borrelia burgdorferi bacteria, which causes the illness. Tarsus Pharmaceuticals is working on TP-05, while Moderna is exploring mRNA-based vaccines with mRNA-1982 and mRNA-1975. These therapies represent a diverse range of approaches, from traditional vaccines to cutting-edge mRNA technology, indicating a dynamic and evolving research landscape.
The projected market growth is not solely attributed to these advancements. The report also points to the increasing global healthcare spending as a contributing factor. As healthcare systems worldwide allocate more resources to infectious disease management and preventative care, the Lyme disease market is expected to benefit. The rising incidence of Lyme disease, potentially linked to climate change and expanding tick habitats, also contributes to the anticipated market expansion. This growing patient population creates a greater demand for effective treatments and preventative strategies, further driving market growth. The combination of innovative therapies and a growing patient base suggests a promising future for the Lyme disease treatment market, offering hope for better prevention and management of this increasingly prevalent disease.
Lyme disease, a bacterial infection transmitted through the bite of infected blacklegged ticks, can cause a range of symptoms, from fever and fatigue to more serious complications affecting the joints, heart, and nervous system. The current treatment landscape primarily relies on antibiotics, but the emergence of new therapies offers hope for improved patient outcomes and preventative measures.
DelveInsight’s analysis highlights several key players and their groundbreaking approaches. Valneva and Pfizer are jointly developing VLA15, a vaccine designed to prevent Lyme disease by targeting the outer surface protein of the Borrelia burgdorferi bacteria, which causes the illness. Tarsus Pharmaceuticals is working on TP-05, while Moderna is exploring mRNA-based vaccines with mRNA-1982 and mRNA-1975. These therapies represent a diverse range of approaches, from traditional vaccines to cutting-edge mRNA technology, indicating a dynamic and evolving research landscape.
The projected market growth is not solely attributed to these advancements. The report also points to the increasing global healthcare spending as a contributing factor. As healthcare systems worldwide allocate more resources to infectious disease management and preventative care, the Lyme disease market is expected to benefit. The rising incidence of Lyme disease, potentially linked to climate change and expanding tick habitats, also contributes to the anticipated market expansion. This growing patient population creates a greater demand for effective treatments and preventative strategies, further driving market growth. The combination of innovative therapies and a growing patient base suggests a promising future for the Lyme disease treatment market, offering hope for better prevention and management of this increasingly prevalent disease.
Category:
Technology